SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (1575)1/13/1999 5:20:00 PM
From: Rudy Saucillo  Read Replies (2) | Respond to of 2173
 
My point is that the FDA will not approve this drug candidate based on subgroup analysis. The subgroup analysis itself is meaningless since the analysis doesn't show what patients *statistically speaking* may benefit from usage *prior to the actual usage*! And *yes* the FDA is very concerned about what patient populations will respond to drug - irrespective of which NDA you want to discuss.

Rudy


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News